Eric Lefebvre - Jul 9, 2024 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)

Role: Chief Medical Officer
Signature: /s/ Mike Ouimette, attorney-in-fact
Stock symbol: PLRX
Transactions as of: Jul 9, 2024
Transactions value $: $0
Form type: 4
Date filed: 7/11/2024, 05:01 PM
Previous filing: Mar 22, 2024
Next filing: Jul 12, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PLRX	Common Stock	Award	$0	+24.1K	+11.95%	$0.00	225K	Jul 9, 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On July 28, 2022, the Reporting Person was granted 87,500 performance-vested stock units, the vesting of which were subject to the achievement of various pre-established performance criteria. On July 9, 2024, the Compensation Committee of the Issuer's Board of Directors certified the achievement of the performance criteria tied to the company's total shareholder return relative to the Nasdaq Biotechnology Index, resulting in the vesting of 24,063 shares.
F2	Includes 1,488 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program.

Content

On July 28, 2022, the Reporting Person was granted 87,500 performance-vested stock units, the vesting of which were subject to the achievement of various pre-established performance criteria. On July 9, 2024, the Compensation Committee of the Issuer's Board of Directors certified the achievement of the performance criteria tied to the company's total shareholder return relative to the Nasdaq Biotechnology Index, resulting in the vesting of 24,063 shares.

Includes 1,488 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program.